About the Conference
The 13th edition of the Brazilian Lymphoma Conference (BLC 2023), a 3 1/2-day conference, will be held exclusively online this year from March 29 to April 1.
As a result of many people's work, the BLC has become the most significant event on lymphoproliferative diseases in Latin America due to the number of attendees and the acknowledgment of national and international experts.
The updated scientific content, mainly focusing on the remarkable advances already published or submitted at recent meetings, presents a critical view of these studies, particularly in their relevance in countries with less financial resources, given the high cost of these new treatments.
Main Topics:
Hot Topics Session: MRD in Lymphomas and CLL
Magna: International Conference on Malignant Lymphoma: Lessons from Lugano
Magna: International Conference on Malignant Lymphoma: Lessons from Lugano
Organizing Committee
PRESIDENT
Carlos Sergio Chiattone
FCM da Santa Casa de São Paulo e Hospital Samaritano - SP
Comitê Organizador
Celso Arrais
UNESP e DASA
ORGANIZING COMMITTEE
Guilherme Perini
Hospital Israelita Albert Einstein e Grupo Américas
ORGANIZING COMMITTEE
Jorge Vaz Pinto Neto
Cettro (Centro de Cancer de Brasília)
ORGANIZING COMMITTEE
Natalia Zing
BP - A Beneficência Portuguesa de São Paulo
ORGANIZING COMMITTEE
Talita Silveira
AC Camargo Cancer Center
ORGANIZING COMMITTEE
Thais Fisher
AC Camargo Cancer Center
Speakers
Adriana Scheliga
Grupo Oncoclínicas
Alexey Danilov
City of Hope National Medical Center
André Neder Ramires Abdo
ICESP e Hospital Alemão Oswaldo Cruz
Andrea Gallamini
A. Lacassagne Cancer Center
Andrés J. M. Ferreri
IRCCS San Raffaele Scientific Institute
Andrew Davies
Southampton General Hospital
Andrew Zelenetz
Memorial Sloan Kettering Cancer Center (MSKCC)
Angelo Maiolino
ABHH / UFRJ e Grupo Américas
Anna Maria Sureda
Blood Cell Barcelona Hematology Institute Hospital Universitari Dexeus
Carsten Utoft Niemann
Rigshospitalet, Copenhagen University Hospital
Christian Steidl
BC CANCER RESEARCH CENTRE
Christiane Pott
University Hospital Schleswig-Holstein
Christopher Kelsey
Duke University
Craig Moskowitz
University of Miami Health System
Danielle Leão
Hospital BP - A Beneficência Portuguesa de São Paulo
Eduardo Flávio Oliveira Ribeiro
UNB e Hospital Santa Lúcia/DF
Emanuele Zucca
Oncology Institute of Southern Switzerland, Ospedale San Giovanni
Flávia Xavier
UNB
Franco Cavalli - Magna
Foundation for the Institute on Oncology Research (IOR)
Guilherme Perini
Hospital Israelita Albert Einstein e Grupo Américas
Isabela Gonçalves Antunes Pereira
Dasa Oncologia
Joana Koury
Fundação HEMOPE
John Pagel
Lilly / Seattle Cancer Care Alliance
Jorge Castillo
Harvard Medical School / Dana-Farber Cancer Institute
Luis Fayad
MD Anderson Cancer Center
Márcio Nucci
UFRJ
Mark Roschewski
NHI - National Cancer Institute / Center for Cancer Research
Martin Hutchings
University of Copenhagen
Massimo Federico
Università degli Studi di Modena e Reggio Emilia
Natália Zing
BP - A Beneficência Portuguesa de São Paulo
Nathan Fowler
Bostongene / Georgetown University
Otávio Baiocchi
Unifesp / Hospital Alemão Oswaldo Cruz
Owen O Connor
University of Virginia Comprehensive Cancer Center
Paolo Ghia
Università Vita-Salute San Raffaele
Paul Bröckelmann
University Hospital of Cologne, Germany German Hodgkin Study Group (GHSG)
Renato Cunha
Grupo Oncoclínicas
Robin Foà
University of Rome
Salvia Jain
Massachusetts General Hospital
Samir Nabhan
UFPR
Stefano Luminari
University of Modena and Reggio Emilia
Talita Silveira
AC Camargo Cancer Center
Thais Fischer
AC Camargo Cancer Center
REGISTRATION
ABHH MEMBER
FREE
- 2023 paid annuity
NON-MEMBER
R$ 150,00*
* Registration will only be effective after payment has been confirmed. You must use the email and password you registered to access the conference-broadcasting plataform.
Withdrawal and Reimbursement
The request for registration cancelation and reimbursement should be sent to the Secretariat until March 28, 2023. After this date, no cancelation will be accepted.
Reimbursement for the amount paid will be made up to 60 days after the conference and it will correspond to 60% of the amount paid.
Click here to download the request for reimbursement.
Please send the request properly signed and scanned to the email: eventos@abhh.org.br
SIMULTANEOUS TRANSLATION
International speakers’ lectures and the Live sessions of Questions and Answers will rely on simultaneous translation (English/Portuguese).
Please select the language-corresponding flag on the upper corner of the screen.
Wednesday, March 29th, 2023 - Day 1
13:30 - 13:40
Opening
Presidente / President ABHH: José Francisco Comenalli Marques Jr. (BRA)
Presidente / Chair BLC: Carlos Sérgio Chiattone (BRA)
13:40 - 14:40
Session 1: Aggressive Lymphomas I
Moderadores / Moderators: Guilherme Perini (BRA) & Otávio Baiocchi (BRA)
13:40 - 14:00
The importance of tumor microenvironment for classification and treatment
Palestrante / Speaker: Christian Steidl (CA)
14:00 - 14:20
What is the best front-line treatment for “DLBCL-NOS” and “High Grade B-cell Lymphoma with MYC and BCL2 or BCL6 rearrangements”
Palestrante / Speaker: Andrew Davies (UK)
14:20 - 14:40
Live Q & A session
14:40 - 15:40
Session 2: Aggressive Lymphomas II
Moderadores / Moderators: Daniel Goldberg Tabak (BRA) & Marco Aurélio Salvino (BRA)
14:40 - 15:00
What is the role of radiotherapy in treating DLBCL: are we missing opportunities?
Palestrante / Speaker: Christopher R Kelsey (USA)
15:00 - 15:20
How to choose the best treatment sequence for R/R DLBCL ?
Palestrante / Speaker: Luis Fayad (USA)
15:20 - 15:40
Live Q & A session
15:40 - 16:00
Break
16:00 - 16:45
Corporate Symposium – MSD
Immunotherapy: Clinical Case discussion about HL and PMBCL treatments (*For prescribers only)
16:00 - 16:05
Opening
Chair: Guilherme Perini
16:05 - 16:15
The role of immunotherapy in CHL and PMBCL
Palestrante / Speaker: Guilherme Perini
16:15 - 16:25
Clinical Case Discussion - CHL
Palestrante / Speaker: Guilherme Perini
16:25 - 16:35
Clinical Case Discussion - PMBCL
Palestrante / Speaker: Talita Silveira
16:35 - 16:45
Discussion and closing
Palestrantes / Speakers: Guilherme Perini e Talita Silveira
16:45 - 17:00
Break
17:00 - 17:45
Corporate Symposium Abbvie: New dimensions in R/R DLBCL and implications for future clinical practice (*For prescribers only)
17:00 - 17:05
Opening
Chair: Guilherme Perini
17:05 - 17:35
New dimensions in R/R DLBCL and implications for future clinical practice
Palestrante / Speaker: Anna Maria Sureda (ES)
17:35 - 17:45
Discussion: Q & A
Palestrante / Speaker: Todos / All
17:45 - 18:45
Session 3: Lymphomas & CNS
Moderadores / Moderators: Talita Maira Bueno da Silveira (BRA) & Thiago Xavier Carneiro (BRA)
17:45 - 18:05
CNS prophylaxis in DLBCL: is it dead? Controversies and beyond
Palestrante / Speaker: Andrés Ferreri (ITA)
18:05 - 18:25
DLCBL first line treatment: what is the patient that has CNS risk infiltration?
Palestrante / Speaker: Andrew Zelenetz (USA)
18:25 - 18:45
Live Q & A session
18:45 - 19:45
Session 4: Lymphomas in elderly and/or frail patients
Moderadores / Moderators: Glaciano Nogueira Ribeiro (BRA) & Laura Maria Fogliatto (BRA)
18:45 - 19:05
How to evaluate risk factors and how to treat elderly patients with DLBCL
Palestrante / Speaker: Stefano Luminari (ITA)
19:05 - 19:25
Management of Hodgkin Lymphoma in the elderly: the best balance between toxicity and efficacy
Palestrante / Speaker: Paul Broeckelmann (GER)
19:25 - 19:45
Live Q & A session
19:45 - 20:50
Session 5: Clinical case discussion I
Comentários / Comments: Belinda Simões (BRA) & Guilherme Duffles (BRA)
19:45 - 20:00
Clinical case 1: DLBCL R/R
Apresentador / Presenter: Thais Fisher (BRA)
20:00 - 20:15
Clinical case 2 : Mantle Cell Lymphoma
Apresentador / Presenter: Natalia Zing (BRA)
20:15 - 20:30
Clinical case 3: panniculitis-like PTCL
Apresentador / Presenter: Joana Koury (BRA)
20:30 - 20:50
Live Q & A session
* The content of some Corporate Symposia is only for attendees based on the compliance policy of each company promoting the activity.
Thursday, March 30th, 2023 - Day 2
13:30 - 14:15
Corporate Symposium – Lilly
Mantle cell lymphoma: unmet needs and current scenario (*For prescribers only)
13:30 - 13:31
Welcome & introductions
Chair: Carlos Chiattone (BRA)
13:30 - 13:45
Presentation: Unmet needs in the treatment of patients with Mantle Cell Lymphoma and the treatment scenario after covalent iBTKs
Palestrante / Speaker: John Pagel (USA)
13:45 - 14:00
Discussion
Debatedores / Debaters: John Pagel (USA), Carlos Chiattone (BRA), Sérgio Brasil (BRA)
14:00 - 14:15
Audience Q&A
Debatedores / Debaters: John Pagel (USA), Carlos Chiattone (BRA), Sérgio Brasil (BRA)
14:15 - 15:15
Session 6: Mantle Cell Lymphoma
Moderadores / Moderators: Rony Schaffel (BRA) & Sergio Brasil (BRA)
14:15 - 14:35
Should we modify MCL first-line therapy after recent trials results?
Palestrante / Speaker: Alexey Danilov (USA)
14:35 - 14:55
Relapsed/refractory MCL: Therapy Directions in 2023
Palestrante / Speaker: Christiane Pott (GER)
14:55 - 15:15
Live Q & A session
15:15 - 16:15
Session 7: Chronic Lymphocytic Leukemia
Moderadores / Moderators: Celso Arrais (BRA) & Ricardo Bigni (BRA)
15:15 - 15:35
CLL: How to choose the initial therapy for High-risk patients
Palestrante / Speaker: Carsten Utoft Niemann (DK)
15:35 - 15:55
BTKi/BCL-2i time-limited combined treatment: hope or hype?
Palestrante / Speaker: Paolo Ghia (ITA)
15:55 - 16:15
Live Q & A session
16:15 - 16:30
Break
16:30 - 17:15
Corporate Symposium – Takeda
Brentuximab vedotin in the first line of Hodgkin's Lymphoma – Why I am for it vs. Why I am against it (*For prescribers only)
Presidente / Chair: Carlos Sérgio Chiattone (BRA)
Palestrantes / Speakers: Adriana Scheliga (BRA) & Flávia Xavier (BRA)
16:30 - 16:35
Opening
Carlos Sérgio Chiattone (BRA)
16:35 - 16:50
Why I am' for it
Palestrante / Speaker: Adriana Scheliga (BRA)
16:50 - 17:05
Why I am against it
Palestrante / Speaker: Flavia Dias Xavier (BRA)
17:05 - 17:15
Discussion and Q&A
17:15 - 18:15
Session 8: Follicular Lymphoma
Moderadores / Moderators: Jorge Vaz Pinto Neto (BRA) & Jacques Tabacof (BRA)
17:15 - 17:35
Clinical and Biological Tools for to identify high-risk Follicular Lymphoma
Palestrante / Speaker: Massimo Federico (ITA)
17:35 - 17:55
Follicular lymphoma treatment in the 3rd line and beyond
Palestrante / Speaker: Nathan Fowler (USA)
17:55 - 18:15
Live Q & A session
18:15 - 19:15
Session 9: Peripheral T-cell Lymphomas
Moderadores / Moderators: Juliana Pereira (BRA) & Carlos S. Chiattone (BRA)
18:15 - 18:35
Rethinking CHOP-Based Chemotherapy in the Frontline Treatment of PTCL: It is Time to Think Outside the Box
Palestrante / Speaker: Owen O’Connor (USA)
18:35 - 18:55
Management of R/R T-Cell lymphomas / Evolution of the global outcomes for patients with R/R PTCL in the contemporary era
Palestrante / Speaker: Salvia Jain (USA)
18:55 - 19:15
Live Q & A session
19:15 - 19:30
Break
19:30 - 20:15
Corporate Symposium Zodiac
Considerations of B-lymphoproliferative diseases therapy (*For prescribers only)
Speaker: Thais Fischer (BRA) e Natália Zing (BRA)
* The content of some Corporate Symposia is only for attendees based on the compliance policy of each company promoting the activity.
Friday, March 31th, 2023 - Day 3
13:30 - 14:15
Corporate Symposium – Roche
DLBCL: Profiling Genetic Signature and Advances in 1st line Treatment (*For prescribers only)
Co-Apresentadores / Hosts: Otávio Baiocchi (BRA) e Juliana Pereira (BRA)
14:15 - 14:30
Break
14:30 - 15:15
Corporate Symposium – Kite
CAR-T therapy in R/R DLBCL: Current progress and future strategies
Chairman: Jayr Schmidt (BRA)
Palestrante / Speaker: Samir Nabhan (BRA)
15:15 - 16:15
Session 10: Lymphomas: novel therapies
Moderadores / Moderators: Vanderson Rocha & Jayr Schmidt Filho
15:15 - 15:35
Bispecific monoclonal antibodies: are they really coming to practice?
Palestrante / Speaker: Martin Hutchings (DK)
15:35 - 15:55
DLBCL: bridging therapy options for CAR-T cell
Palestrante / Speaker: Renato Luiz Guerino Cunha (BRA)
15:55 - 16:15
Live Q & A session
16:15 - 17:15
Session 11: Hodgkin Lymphoma
Moderadores / Moderators: Valéria Buccheri (BRA) & Irene de Almeida Biasoli (BRA)
16:15 - 16:35
Front Line Therapy: risk adapted and response adapted front line therapy
Palestrante / Speaker: Craig Moscowitz (USA)
16:35 - 16:55
R/R CHL: How to treat?
Palestrante / Speaker: Otávio Baiocchi (BRA)
16:55 - 17:15
Live Q & A session
17:15 - 18:00
Session 12: Access to novel therapies for onco-hematological diseases
Moderadores / Moderators: José Francisco Comenalli Marques Jr. (BRA) e Fernando Barroso (BRA)
17:15 - 17:35
If the internationally accepted evidence is not considered satisfactory by the paying sources, what is the medical associations´s role?
Palestrante / Speaker: Angelo Maiolino (BRA)
17:35 - 18:00
Live Q & A session
* The content of some Corporate Symposia is only for attendees based on the compliance policy of each company promoting the activity.
Saturday, April 1st, 2023 - Day 4
08:00 - 09:00
Session 13: Lymphoproliferative diseases: issues in evidence
Moderadores / Moderators: Márcia Torresan Delamain (BRA) & Yana Novis (BRA)
08:00 - 08:20
Waldenström Macroglobulinemia: Has the time for chemo-free treatment come?
Palestrante / Speaker: Jorge Castillo (USA)
08:20 - 08:40
Role of Radiomics-based PET/CT in Lymphoma: diagnosis, prognosis and response
Palestrante / Speaker: Andrea Gallamini (ITA)
08:40 - 09:00
Live Q & A session
09:00 - 10:20
Session 14: Lymphomas and CLL: 2022 Review
Moderadores / Moderators: Jorge Vaz Pinto Neto (BRA) & Celso Arrais (BRA)
09:00 - 09:20
Overview on the International Extranodal Lymphoma Study Group Annual Meeting- 2023
Palestrante / Speaker: Emanuele Zucca (CH)
09:20 - 09:40
Lymphomas: Best of ASCO, EHA and ASH 2022
Palestrante / Speaker: Danielle Leão (BRA)
09:40 - 10:00
CLL: Best of ASCO, EHA and ASH 2022
Palestrante / Speaker: Adriana Scheliga (BRA)
10:00 - 10:20
Live Q & A session
10:20 - 11:20
Session 15: Infection and Lymphoproliferative Disorders
Moderadores / Moderators: Samir Kanaan Nabhan (BRA) & Marcelo Bellesso (BRA)
10:20 - 10:40
Managing and Preventing CLL Infection
Palestrante / Speaker: Marcio Nucci (BRA)
10:40 - 11:00
Does Covid still impact lymphoma care? How?
Palestrante / Speaker: Guilherme Perini (BRA)
11:00 - 11:20
Live Q & A session
11:20 - 12:10
Key-note Conference
Moderador / Moderator: Carlos S. Chiattone (BRA)
11:20 - 11:50
INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA: Lessons from Lugano
Palestrante / Speaker: Franco Cavalli (CH)
11:50 - 12:10
Live Q & A session
Participantes / Participantes: Todos / All
12:10 - 13:10
Session 16: Hot Topics
Moderadores / Moderators: Rodrigo Calado (BRA) & Phillip Scheinberg (BRA)
12:10 - 12:30
Is There a Role for Circulating Tumor DNA in DLBCL Management?
Palestrante / Speaker: Mark Roschewski (USA)
12:30 - 12:50
Does MRD have a role in the management of Indolent Lymphomas?
Palestrante / Speaker: Robin Foà (ITA)
12:50 - 13:10
Live Q & A session
13:10 - 14:25
Session 17: Clinical case discussion II
Comentários / Comments: Yung Bruno de Mello Gonzaga (BRA) & Diego Villa Clé (BRA)
13:10 - 13:25
Clinical case 4: Richter Transformation
Apresentador / Presenter: Isabela Gonçalves Antunes Pereira (BRA)
13:25 - 13:40
Clinical case 5: Primary Cutaneous Anaplastic Large Cell Lymphoma
Apresentador/ Presenter: André Neder Ramires Abdo (BRA)
13:40 - 13:55
Clinical case 6: R/R Hodgkin Lymphoma
Apresentador/ Presenter: Eduardo Flávio Oliveira Ribeiro (BRA)
13:55 - 14:25
Live Q & A session
Participantes / Participants: Todos / All
14:25 - 14:40
Closing
Presidente / Chair BLC: Carlos Chiattone (BRA)
* The content of some Corporate Symposia is only for attendees based on the compliance policy of each company promoting the activity.
GENERAL INFORMATION
The access to the broadcasting platform will be through the link www.abhheventos.com, please use the data entered at registration (email and password). You will be able to access it from March 28th.
Please access our chat, on the bottom right icon of the website or www.abhheventos.com. If you prefer, you can reach us through email:
eventos@abhh.org.br
In case you need support during the broadcasting, our communication channels will be available.
In case you need support during the broadcasting, our communication channels will be available.
If you are trying to enter your password but it is not right, you should be driven to other page to recover your password.
Please try again or use a different email address you often use.
The content of some Corporate Symposia is only for attendees based on the compliance policy of each company promoting the activity.
A certificate will be awarded to all attendees. It should be available 7 days after the event. Please access the Restricted Area of this website using your email and password registered.
*It is mandatory to have attended to 70% of total workload of the conference.
*It is mandatory to have attended to 70% of total workload of the conference.
Lectures will be available through a link and will be made available to all attendees 30 days after the conference.
ABHH members may access as well through Hemoteca on the website
www.abhh.org.brin the Education Section.
- Use the Google Chrome browser.
- Check if the place chosen has a good internet signal and if your computer battery is loaded (or make sure you are close to a power source).
- Test your connection through the internet address: www.speedtest.net
- If you are using the company computer, it may have safety protocols that might interfere. If that is the case, please use your personal computer.
- Choose your desktop over a tablet or mobile device.
- Close all the windows and software not necessary to access the event.
- Make sure every pop-up blockage software on your browser is off.
- Remember to disable the VPN in your computer settings.
- Try an incognito window on your web browser.
- Choosing a calm place, and if possible a quiet place, will help in your concentration.
- Access the conference link 1 hour in advance, so you can check the places available in the platform.
- Use the programme breaks to stretching, drinking some water, checking your messages, etc.
- Remember to interact through the chat and interaction tools.
SPONSORS
Gold
Silver
Bronze
Support
